Dimerix

Dimerix Equity Growth

The Year-over-Year Equity Growth of Dimerix (DXB.AX) as of Oct 11, 2026 is -210.30 %. In the previous year, Year-over-Year Equity Growth was -26.43 % — a change of 695.71% (lower).

Equity Growth

-210.30 %

YoY

695.71%

Last updated:

Year-over-Year Equity Growth of Dimerix is 2026 -210.30 % . Year-over-Year Equity Growth of Dimerix was 2025 -26.43 % . It decreases by 695.71% lower compared to the previous year.

The Dimerix Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2019
-38.72 AUD
Jan 1, 2020
84.62 AUD
Jan 1, 2021
-81.07 AUD
Jan 1, 2022
882.13 AUD
Jan 1, 2023
-58.65 AUD
Jan 1, 2024
204.97 AUD
Jan 1, 2025
-26.43 AUD
Jan 1, 2026
-210.30 AUD
The Dimerix Equity Growth history
YEAREquity GrowthYoY
-210.30 %+695.71%
-26.43 %-112.89%
204.97 %-449.45%
-58.65 %-106.65%
882.13 %-1,188.06%
-81.07 %-195.81%
84.62 %-318.56%
-38.72 %-124.08%
160.79 %+831.51%
17.26 %-189.68%
-19.25 %-100.22%
8,796.37 %—
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Year-over-Year Equity Growth of Dimerix is -210.30 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Dimerix since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Dimerix historically and in real time.

Access this data via the Eulerpool API

Growth — Dimerix

All Key Metrics — Dimerix